Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1

Cell Death and Differentiation

Volumn 21, Issue 6, 2014, Pages 929-940

  Bageritz, J ^a   Puccio, L ^a   Piro, R M ^a,b   Hovestadt, V ^a   Phillips, E ^a   Pankert, T ^b   Lohr, J ^b   Herold Mende, C ^b   Lichter, P ^a   Goidts, V ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD133; cell cycle; ecto nucleotidase; glioblastoma stem like cells; RNAi screen

Indexed keywords

CD133 ANTIGEN; NUCLEOTIDASE; NUCLEOTIDE PYROPHOSPHATASE; PROTEIN ENPP1; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; E2F1 PROTEIN, HUMAN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; GLYCOPROTEIN; INORGANIC PYROPHOSPHATASE; LEUKOCYTE ANTIGEN; PEPTIDE; PHOSPHODIESTERASE;

ARTICLE; CANCER STEM CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LINEAGE; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; DIFFERENTIATION; GENE EXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA STEM LIKE CELL; HUMAN; HUMAN CELL; NEURAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; THERAPY RESISTANCE; TUMOR RECURRENCE; BIOSYNTHESIS; BRAIN TUMOR; CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; NEURAL STEM CELLS; PEPTIDES; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES;

EID: 84899956176     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.12     Document Type: Article

References (60)

1. Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39:193-206.
4. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
5. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
7. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir I et al. Analysis of gene expression and chemoresistance of CD133 + cancer stem cells in glioblastoma. Mol Cancer2006; 5:67.
8. Son MJ, Woolard K, Nam D-H, Lee J, Fine HA. SSEA-1 Is an enrichment marker for tumor-nitiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-452.
9. Toda M, Iizuka Y, Yu W, Imai T, Ikeda E, Yoshida K et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001; 34:1-7.
10. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
11. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-768.
12. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-8212.
13. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-129.
14. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 2013; 31: 857-869.
15. Wurdak H, Zhu S, Romero A, Lorger M, Watson J, Chiang C-y et al. An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem Cell 2010; 6: 37-47.
16. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-2728.
17. Aerts I, Martin JJ, De Deyn PP, Van Ginniken C, Van Ostade X, Kockx M et al. The expression of ecto-nucleotide pyrophosphatase/phospho-diesterase 1 (E-NPP1) is correlated with astrocytic tumor grade. Clin Neurol Neurosurg 2011; 113: 224-229.
18. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010; 51: 297-305.
19. Chen Q, Zhou Y, Zhao X, Zhang M. Effect of dual-specificity protein phosphatase 5 on pluripotency maintenance and differentiation of mouse embryonic stem cells. J Cell Biochem 2011; 112: 3185-3193.
20. Liu Q, Nguyen D, Dong Q, Shitaku P, Chung K, Liu O et al. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 2009; 94: 1-19.
21. Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev 2009; 23: 837-848.
22. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011; 128: 1095-1103.
23. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009; 4: 568-580.
24. Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci USA 2011; 108: 1591-1596.
25. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011; 71: 1772-1780.
26. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol 2000; 35: 393-432.
27. Salomoni P, Calegari F. Cell cycle control of mammalian neural stem cells: putting a speed limit on G1. Trends Cell Biol 2010; 20: 233-243.
28. Molineris I, Grassi E, Ala U, Di Cunto F, Provero P. Evolution of promoter affinity for transcription factors in the human lineage. Mol Biol Evol 2011; 28: 2173-2183.
29. Piccirillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-765.
30. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S et al. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012; 31: 3235-3243.
31. Mak AB, Blakely KM, Williams RA, Penttilä P-A, Shukalyuk AI, Osman KT et al. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem 2011; 286: 41046-41056.
32. Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012; 8: 437-502.
33. Takahashi T, Old LJ, Boyse EA. Surface alloantigens of plasma cells. J Exp Med 1970; 131: 1325-1341.
34. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009; 29: 8884-8896.
35. Nakata S, Campos B, Bageritz J, Lorenzo Bermejo J, Becker N, Engel F et al. LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 2013; 23: 60-72.
36. Lange C, Calegari F. Cdks and cyclins link G1 length and differentiation of embryonic, neural and hematopoietic stem cells. Cell Cycle 2010; 9: 1893-1900.
37. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 2008; 9: 115-128.
38. Singh AM, Dalton S. The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 2009; 5: 141-149.
39. Chirasani SR, Sternjak A, Wend P, Momma S, Campos B, Herrmann IM et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010; 133(Pt 7): 1961-1972.
40. Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR et al. Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 2011; 30: 3454-3467.
41. Palm T, Hemmer K, Winter J, Fricke IB, Tarbashevich K, Sadeghi Shakib F et al. A systemic transcriptome analysis reveals the regulation of neural stem cell maintenance by an E2F1-miRNA feedback loop. Nucleic Acids Res 2013; 41: 3699-3712.
42. Yeo HC, Beh TT, Quek JJ, Koh G, Chan KK, Lee DY. Integrated transcriptome and binding sites analysis implicates E2F in the regulation of self-renewal in human pluripotent stem cells. PLoS One 2011; 6: e27231.
43. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 2008; 133: 1106-1117.
44. Ipata PL. Origin, utilization, and recycling of nucleosides in the central nervous system. Adv Physiol Educ 2011; 35: 342-346.
45. Anglana M, Apiou F, Bensimon A, Debatisse M. Dynamics of DNA replication in mammalian somatic cells: nucleotide pool modulates origin choice and interorigin spacing. Cell 2003; 114: 385-394.
46. Neary JT, Zimmermann H. Trophic functions of nucleotides in the central nervous system. Trends Neurosci 2009; 32: 189-198.
47. Ulrich H, Abbracchio M, Burnstock G. Extrinsic purinergic regulation of neural stem/progenitor cells: implications for CNS development and repair. Stem Cell Rev 2012; 8: 755-767.
48. Bergamin LS, Braganhol E, Zanin RF, Edelweiss MI, Battastini AM. Ectonucleotidases in tumor cells and tumor-associated immune cells: an overview. J Biomed Biotechnol 2012; 2012: 959848.
49. Wink MR, Lenz G, Braganhol E, Tamajusuku AS, Schwartsmann G, Sarkis JJ et al. Altered extracellular ATP, ADP and AMP catabolism in glioma cell lines. Cancer Lett 2003; 198: 211-218.
50. Grobben B, Anciaux K, Roymans D, Stefan C, Bollen M, Esmans EL et al. An ecto-nucleotide pyrophosphatase is one of the main enzymes involved in the extracellular metabolism of ATP in rat C6 glioma. J Neurochem 1999; 72: 826-834.
51. Oliver FJ, Collins MKL, López-Rivas A. dNTP pools imbalance as a signal to initiate apoptosis. Experientia 1996; 52: 995-1000.
52. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 2009; 15: 6541-6550.
53. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
54. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
55. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
56. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-378.
57. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
58. Bryne JC, Valen E, Tang M-HE, Marstrand T, Winther O, da Piedade I et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Res 2008; 36: D102-D106.
59. Piro RM, Molineris I, Di Cunto F, Eils R, König R. Disease-gene discovery by integration of 3D gene expression and transcription factor binding affinities. Bioinformatics 2013; 29: 468-475.
60. Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573: 83-92.